Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University and Tianjin Center for International Collaborative Research on Environment, Nutrition and Public Health, Tianjin, China.
Department of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.
Diabetes Res Clin Pract. 2022 Jan;183:109050. doi: 10.1016/j.diabres.2021.109050. Epub 2021 Dec 6.
The approaches used to screen and diagnose gestational diabetes mellitus (GDM) vary widely. We generated a comparable estimate of the global and regional prevalence of GDM by International Association of Diabetes in Pregnancy Study Group (IADPSG)'s criteria.
We searched PubMed and other databases and retrieved 57 studies to estimate the prevalence of GDM. Prevalence rate ratios of different diagnostic criteria, screening strategies and age groups, were used to standardize the prevalence of GDM in individual studies included in the analysis. Fixed effects meta-analysis was conducted to estimate standardized pooled prevalence of GDM by IDF regions and World Bank country income groups.
The pooled global standardized prevalence of GDM was 14.0% (95% confidence interval: 13.97-14.04%). The regional standardized prevalence of GDM were 7.1% (7.0-7.2%) in North America and Caribbean (NAC), 7.8% (7.2-8.4%) in Europe (EUR), 10.4% (10.1-10.7%) in South America and Central America (SACA), 14.2% (14.0-14.4%) in Africa (AFR), 14.7% (14.7-14.8%) in Western Pacific (WP), 20.8% (20.2-21.4%) in South-East Asia (SEA) and 27.6% (26.9-28.4%) in Middle East and North Africa (MENA). The standardized prevalence of GDM in low-, middle- and high-income countries were 12.7% (11.0-14.6%), 9.2% (9.0-9.3%) and 14.2% (14.1-14.2%), respectively.
The highest standardized prevalence of GDM was in MENA and SEA, followed by WP and AFR. Among the three World Bank country income groups, high income countries had the highest standardized prevalence of GDM. The standardized estimates for the prevalence of GDM provide an insight for the global picture of GDM.
用于筛查和诊断妊娠期糖尿病(GDM)的方法差异很大。我们根据国际妊娠糖尿病研究组织(IADPSG)的标准,生成了一个可比较的全球和区域 GDM 患病率估计值。
我们在 PubMed 和其他数据库中进行了检索,以评估 57 项研究中 GDM 的患病率。使用不同诊断标准、筛查策略和年龄组的患病率比率,来标准化分析中包含的各个研究的 GDM 患病率。采用固定效应荟萃分析来估计按 IDF 区域和世界银行国家收入组别标准化的 GDM 总患病率。
全球 GDM 的标准化总患病率为 14.0%(95%置信区间:13.97-14.04%)。GDM 的区域标准化患病率分别为:北美和加勒比地区(NAC)7.1%(7.0-7.2%),欧洲(EUR)7.8%(7.2-8.4%),南美洲和中美洲(SACA)10.4%(10.1-10.7%),非洲(AFR)14.2%(14.0-14.4%),西太平洋(WP)14.7%(14.7-14.8%),东南亚(SEA)20.8%(20.2-21.4%)和中东和北非(MENA)27.6%(26.9-28.4%)。低收入、中等收入和高收入国家的 GDM 标准化患病率分别为 12.7%(11.0-14.6%)、9.2%(9.0-9.3%)和 14.2%(14.1-14.2%)。
MENA 和 SEA 地区的 GDM 标准化患病率最高,其次是 WP 和 AFR。在世界银行三个国家收入组别中,高收入国家的 GDM 标准化患病率最高。GDM 患病率的标准化估计值为全球 GDM 状况提供了一个视角。